Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SENTI 202

Next Previous
Drug Profile

SENTI 202

Alternative Names: SENTI-202

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Senti Biosciences
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 11 Feb 2026 Senti Biosciences announced intention to discuss the next phase of development with US FDA in the first half of 2026
  • 11 Feb 2026 Senti Biosciences completes the Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (Parenteral)
  • 11 Feb 2026 Senti Biosciences plans a clinical trial for Acute myeloid leukemia (Frist-line therapy, In children)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top